• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Vitrolife

87.00 SEK+0.69 %10.7. klo 18.29
Less than 1K followers

VITR

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.69 %
-8.03 %
-8.71 %
-33.33 %
-36.50 %
-40.21 %
-57.77 %
-78.47 %
+1,317.63 %

Vitrolife is an international group that provides medical devices and genetic services. The company develops and manufactures services and products for personalized genetic information as well as medical devices in the field of fertility. Vitrolife supports customers in their operations to improve patient outcomes from fertility treatments. Vitrolife's products and services are available globally. The company is headquartered in Gothenburg, Sweden.

Read more
Market cap
11.78B SEK
Turnover
10.17M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
16.7.
2026

Interim report Q2'26

22.10.
2026

Interim report Q3'26

28.1.
2027

Annual report '26

Press release01.07.2026 klo 16.00

Invitation to Vitrolife Group's presentation of the Q2 2026 interim report

Vitrolife
Vitrolife, Audiocast, Q2'26
Webcast16.07.2026 klo 11.00

Vitrolife, Audiocast, Q2'26

Vitrolife
Press release01.06.2026 klo 13.00

Vitrolife AB (publ): Vitrolife Group appoints Olivier Desmarets as Chief Operations Officer following Ermanno Sironi's retirement

Vitrolife

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release22.05.2026 klo 13.00

Vitrolife AB (publ): CEO Bronwyn Brophy O'Connor has decided to leave Vitrolife Group

Vitrolife
Regulatory press release05.05.2026 klo 19.30

Report from the Annual General Meeting of Vitrolife AB (publ)

Vitrolife
Press release24.04.2026 klo 10.41

Redeye: Vitrolife (Q1 review): Fx-headwind but solid profitability

Vitrolife
Vitrolife, Audiocast, Q1'26
Webcast23.04.2026 klo 11.00

Vitrolife, Audiocast, Q1'26

Vitrolife
Regulatory press release23.04.2026 klo 09.00

Vitrolife AB (publ): Interim report Q1, 2026: Strong growth in Consumables and Technologies

Vitrolife
Press release09.04.2026 klo 10.00

Vitrolife AB (publ): Invitation to Vitrolife Group's presentation of the Q1 2026 interim report

Vitrolife
Regulatory press release01.04.2026 klo 19.00

Notice of the Annual General Meeting of Vitrolife AB (publ)

Vitrolife
Regulatory press release01.04.2026 klo 18.50

Vitrolife AB (publ): The Nomination Committee proposes two new Board members

Vitrolife
Regulatory press release26.03.2026 klo 10.00

Vitrolife AB (publ): Vitrolife Group has today published its Annual and Sustainability Report for 2025

Vitrolife
Press release04.02.2026 klo 10.24

Redeye: Vitrolife (Q4 Review) - Excessive selloff improves risk/reward in the stock

Vitrolife
Vitrolife, Audiocast, Q4'25
Webcast03.02.2026 klo 11.00

Vitrolife, Audiocast, Q4'25

Vitrolife
Regulatory press release03.02.2026 klo 09.00

Vitrolife AB (publ): Fourth quarter and full year report 2025

Vitrolife
Press release20.01.2026 klo 18.36

Vitrolife AB (publ): Invitation to Vitrolife Group's presentation of the fourth quarter and full year report 2025

Vitrolife
Press release22.12.2025 klo 14.05

Redeye: Vitrolife - Updating our view on the case

Vitrolife
Regulatory press release16.12.2025 klo 20.02

Vitrolife AB (publ): Vitrolife announces genetic services restructuring program targeting annualised savings of 65 MSEK and recognises a 5.4 BSEK goodwill impairment

Vitrolife
Press release29.10.2025 klo 10.00

Nomination committee of Vitrolife AB (publ) for the Annual General Meeting 2026

Vitrolife
Vitrolife, Audiocast, Q3'25
Webcast23.10.2025 klo 11.00

Vitrolife, Audiocast, Q3'25

Vitrolife